MOI-A Study
Cross-source consensus on MOI-A Study from 1 sources and 4 claims.
1 sources · 4 claims
Uses
Dosage & preparation
Other
Other
Highlighted claims
- The MOI-A study is an open-label, dose-escalating, randomised phase 2 pilot trial. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose
- The trial aims to identify the Optimal Biologic Dose of losartan for adolescents and adults with osteogenesis imperfecta to inform a later phase III trial. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose
- Participants are randomised equally to target losartan doses of 25 mg, 50 mg, or 75 mg once daily. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose
- The study plans to recruit 30 participants aged 16 years or older with any type of osteogenesis imperfecta across five UK and Italian hospital sites. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose